These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34328191)

  • 61. Distinctly altered gut microbiota in the progression of liver disease.
    Xie G; Wang X; Liu P; Wei R; Chen W; Rajani C; Hernandez BY; Alegado R; Dong B; Li D; Jia W
    Oncotarget; 2016 Apr; 7(15):19355-66. PubMed ID: 27036035
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis.
    Shu W; Shanjian C; Jinpiao L; Qishui O
    Ann Hepatol; 2022; 27(2):100676. PubMed ID: 35093600
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Relationship between intestinal microbial dysbiosis and primary liver cancer.
    Zhang L; Wu YN; Chen T; Ren CH; Li X; Liu GX
    Hepatobiliary Pancreat Dis Int; 2019 Apr; 18(2):149-157. PubMed ID: 30661942
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.
    Sharpton SR; Ajmera V; Loomba R
    Clin Gastroenterol Hepatol; 2019 Jan; 17(2):296-306. PubMed ID: 30196156
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intestinal microbiota and nonalcoholic steatohepatitis.
    Brandl K; Schnabl B
    Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of Intestinal Microbes in Chronic Liver Diseases.
    Xu M; Luo K; Li J; Li Y; Zhang Y; Yuan Z; Xu Q; Wu X
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293518
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature.
    Giuffrè M; Campigotto M; Campisciano G; Comar M; Crocè LS
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G889-G906. PubMed ID: 32146836
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Novel insights in the relationship of gut microbiota and coronary artery diseases.
    Ramírez-Macías I; Orenes-Piñero E; Camelo-Castillo A; Rivera-Caravaca JM; López-García C; Marín F
    Crit Rev Food Sci Nutr; 2022; 62(14):3738-3750. PubMed ID: 33399007
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
    Maccioni L; Gao B; Leclercq S; Pirlot B; Horsmans Y; De Timary P; Leclercq I; Fouts D; Schnabl B; Stärkel P
    Gut Microbes; 2020 Nov; 12(1):1782157. PubMed ID: 32588725
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer.
    Fan X; Jin Y; Chen G; Ma X; Zhang L
    Digestion; 2021; 102(4):508-515. PubMed ID: 32932258
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases.
    Yang X; Lu D; Zhuo J; Lin Z; Yang M; Xu X
    Int J Biol Sci; 2020; 16(13):2357-2366. PubMed ID: 32760203
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The role of the gut microbiota in the pathology and prevention of liver disease.
    Altamirano-Barrera A; Uribe M; Chávez-Tapia NC; Nuño-Lámbarri N
    J Nutr Biochem; 2018 Oct; 60():1-8. PubMed ID: 29653359
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.
    Ghoshal UC; Goel A; Quigley EMM
    Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gut Dysbiosis Associated With Hepatitis C Virus Infection.
    Inoue T; Nakayama J; Moriya K; Kawaratani H; Momoda R; Ito K; Iio E; Nojiri S; Fujiwara K; Yoneda M; Yoshiji H; Tanaka Y
    Clin Infect Dis; 2018 Aug; 67(6):869-877. PubMed ID: 29718124
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Microbiota and viral hepatitis: State of the art of a complex matter.
    Milosevic I; Russo E; Vujovic A; Barac A; Stevanovic O; Gitto S; Amedei A
    World J Gastroenterol; 2021 Sep; 27(33):5488-5501. PubMed ID: 34588747
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Gut Microbiome and Hepatocellular Carcinoma.
    Akkız H
    J Gastrointest Cancer; 2021 Dec; 52(4):1314-1319. PubMed ID: 34870783
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
    Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
    Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
    Huang W; Kong D
    Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.